Marketing Authorization Application for Alitretinoin Accepted by
European Health Authorities
Basel, Switzerland, October 11, 2007 - Basilea Pharmaceutica Ltd.
(SWX:BSLN) announced today that the Marketing Authorization
Application (MAA) for alitretinoin submitted to various EU Member
States was accepted for review under the decentralized procedure.
This application supports the proposed use of oral alitretinoin in
patients with severe refractory chronic hand eczema.
The Marketing Authorization Application (MAA) seeks approval for oral
alitretinoin for the treatment of severe refractory chronic hand
eczema (CHE) and is based on a clinical program comprising almost
2000 patients. Recently, a market authorization application for
alitretinoin in severe refractory CHE has been submitted with the
Swiss health authority Swissmedic.
About Chronic Hand Eczema
Hand eczema is a common skin disease and is often chronic and
relapsing. It is estimated to affect up to 10% of the general
population. The more severe, chronic form of the condition is thought
to affect up to 7% of these patients, many of whom do not respond, or
no longer respond to topical corticosteroids. Basilea estimates there
are at least five hundred thousand patients in Europe with refractory
severe CHE.
About Basilea
Basilea Pharmaceutica Ltd. is an integrated biopharmaceutical company
headquartered in Basel, Switzerland, listed on the SWX Swiss Exchange
(SWX:BSLN). Basilea is currently focused on the research, development
and commercialization of new antibacterial, antifungal and
dermatology drugs in the hospital and specialty care setting.
Disclaimer
This communication expressly or implicitly contains certain
forward-looking statements concerning Basilea Pharmaceutica Ltd. and
its business. Such statements involve certain known and unknown
risks, uncertainties and other factors, which could cause the actual
results, financial condition, performance or achievements of Basilea
Pharmaceutica Ltd. to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing
this communication as of this date and does not undertake to update
any forward-looking statements contained herein as a result of new
information, future events or otherwise.
For further information, please contact:
+----------------------------------------------------------+
| General Information | Investor Relations |
|-------------------------+--------------------------------|
| information@basilea.com | Dr. Barbara Zink |
| | investor_relations@basilea.com |
+----------------------------------------------------------+
This press release can be downloaded from www.basilea.com
The press release can also be downloaded from the following link:
